Breast and ovarian cancer screening of non-carriers from BRCA1/2 mutation-positive families: 2-year follow-up of cohorts from France and Quebec
Michel Dorval, Catherine Noguès, Pascaline Berthet, Jocelyne Chiquette, Marion Gauthier-Villars, Christine Lasset, Claude Picard, Marie Plante, INHERIT BRCAs, GENEPSO Cohort, Jacques Simard, Claire Julian-Reynier, Hélène Cannoni-Zattara, Olivier Capron, Hélène Dreyfus, Thierry Frebourg, Marc Frenay, Jean-Pierre Fricker, Paul Gesta, Rosine Guimbaud, Caroline Logeat, Elisabeth Luporsi, Nguyen Tan Dat, Hagay Sobol, Laurence Venat-Bouvet, Philippe Vennin, Paul Bessette, Peter Bridge, Rachel Laframboise, Bernard Lespérance, Roxane Pichette, Jean Lépine, Elizabeth Maunsell, Louise Provencher, Patricia Voyer, Michel Dorval, Catherine Noguès, Pascaline Berthet, Jocelyne Chiquette, Marion Gauthier-Villars, Christine Lasset, Claude Picard, Marie Plante, INHERIT BRCAs, GENEPSO Cohort, Jacques Simard, Claire Julian-Reynier, Hélène Cannoni-Zattara, Olivier Capron, Hélène Dreyfus, Thierry Frebourg, Marc Frenay, Jean-Pierre Fricker, Paul Gesta, Rosine Guimbaud, Caroline Logeat, Elisabeth Luporsi, Nguyen Tan Dat, Hagay Sobol, Laurence Venat-Bouvet, Philippe Vennin, Paul Bessette, Peter Bridge, Rachel Laframboise, Bernard Lespérance, Roxane Pichette, Jean Lépine, Elizabeth Maunsell, Louise Provencher, Patricia Voyer
Abstract
We described and compared breast and ovarian screening practices in the 2-year period following test result disclosure in female non-carriers from BRCA1/2 mutation-positive families living in two countries, France and Quebec, Canada, which provide universal health care. Four hundred and two (France n=293; Quebec n=109) unaffected female non-carriers from BRCA-proven mutation families provided information about the uptake of mammography, clinical breast examination, breast self-examination, and ovarian ultrasounds using self-administered questionnaires. The frequency of screening practices between study cohorts were compared using logistic regression. Annual mammography was conducted in 23 and 43% of French and Quebecer women participants <50 years of age, respectively (adjusted odds ratio (aOR)=2.72; 95% confidence interval (CI), 1.08-6.81). In women ≥ 50 years of age, mammography was conducted in 49 and 65% of French and Quebecer participants (aOR=1.77; 95% CI, 0.07-4.51). Overall, 33% of French women and 39% of Quebecer women underwent at least one ovarian ultrasound during the 2-year period following BRCA1/2 test result with no significant difference between cohorts of women < 50 years of age. Among older women, Quebecers reported more frequently than French women that they had undergone ultrasound once (aOR=3.00; 95% CI, 1.02-8.83). The frequency of cancer screening practices for female non-carriers from BRCA1/2 mutation-positive families in both France and Quebec exceeded those recommended for similarly aged women in the general population. Our findings highlight the need for clearcut recommendations on the follow-up of women from BRCA1/2 families who are not themselves carriers of a BRCA1/2 mutation.
Figures
Source: PubMed